<DOC>
	<DOC>NCT00147212</DOC>
	<brief_summary>The main purpose of this study is to find out what effects (good or bad) trabectedin (ET743) has on men with advanced prostate carcinoma.</brief_summary>
	<brief_title>ET 743 (Yondelis) in Men With Advanced Prostate Cancer</brief_title>
	<detailed_description>- Treatment with trabectedin will be given once a week for three consecutive weeks with one week of no treatment. This four week period constitutes one cycle. - Trabectedin is given as an infusion through a central venous catheter and is administered over 3 hours. - On day 1 of each cycle a history, physical exam and blood tests will be performed and trabectedin will be administered. - On day 8 and day 15 of each cycle blood work will be performed and trabectedin will be administered. - Patients will continue to receive trabectedin as long as there is no disease progression or unacceptable side effects. - Scans (CT, MRI or bone) or x-rays may be done while the patient is on the trial at the discretion of the physician.</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<criteria>Histologically confirmed adenocarcinoma of the prostate Radiographically documented metastatic disease Surgical or chemical castration Prostate specific antigen (PSA) &gt; 5 ng/ml Castration resistant prostate cancer (CRPC) One previous taxanebased chemotherapy regimen Eastern Cooperative Group (ECOG) performance status 0,1 or 2 Neutrophil count &gt; 1,500/ul Platelet count &gt; 100,000/ul Serum bilirubin &lt; 1.0 x upper limit normal (ULN) Serum alkaline phosphatase &lt; 1.5 x ULN Asparate aminotransferase/Alanine aminotransferase &lt; 2.5 x ULN Albumin &gt; 2.5 g/dl Serum creatinine &lt; 1.5 x ULN Prior hormonal therapy Chemotherapy treatment within 4 weeks of study entry Patient not employing adequate contraception Serious illness or medical conditions, specifically: uncontrolled congestive heart failure or history of myocardial infection or active angina pectoris within 6 months; active infectious process; chronic active liver disease, including chronic hepatitis B, C or cirrhosis Current anticancer treatment with any nonFDA approved investigational drug</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Advanced Prostate Cancer</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Trabectedin</keyword>
	<keyword>ET 743</keyword>
	<keyword>Yondelis</keyword>
</DOC>